Literature DB >> 1918322

Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats.

Y Kuroda1, Y Shimamoto.   

Abstract

The effect of human recombinant tumor necrosis factor-alpha (TNF) on experimental allergic encephalomyelitis (EAE) was studied in Lewis rats. TNF was injected intraperitoneally at a daily dose of 1 x 10(3) or 2 x 10(4) U for 8 consecutive days from one day after sensitization with guinea-pig spinal cord in complete Freund's adjuvant. All rats in the control group developed clinical signs of EAE but recovered within 8 days after the onset. Injections of 2 x 10(4) U/day of TNF resulted in a significant prolongation of clinical EAE: clinical signs were sustained for up to 15 days after onset. Histologically, rats receiving 2 x 10(4) U/day of TNF had more severe cellular infiltrations in the spinal cord than controls. The augmentation of EAE was not found in rats receiving 1 x 10(3) U/day of TNF or TNF that had been neutralized with anti-TNF monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918322     DOI: 10.1016/0165-5728(91)90125-q

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  24 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

4.  Cellular changes underlying hyperoxia-induced delay of white matter development.

Authors:  Thomas Schmitz; Jonathan Ritter; Susanne Mueller; Ursula Felderhoff-Mueser; Li-Jin Chew; Vittorio Gallo
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

5.  Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets.

Authors:  Junpeng Wang; Zhihong Ren; Yanmei Xu; Sheng Xiao; Simin N Meydani; Dayong Wu
Journal:  Am J Pathol       Date:  2011-11-03       Impact factor: 4.307

6.  Theiler's murine encephalomyelitis virus induces tumour necrosis factor-alpha in murine astrocyte cell cultures.

Authors:  A Sierra; N Rubio
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

Review 7.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

8.  Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha.

Authors:  L Probert; K Akassoglou; M Pasparakis; G Kontogeorgos; G Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells.

Authors:  Joel M Dopp; Theodore A Sarafian; Francesca M Spinella; Michelle A Kahn; Hungyi Shau; Jean de Vellis
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 10.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.